Clinical Trials Logo

Rheumatoid Arthritis clinical trials

View clinical trials related to Rheumatoid Arthritis.

Filter by:

NCT ID: NCT01270997 Completed - Clinical trials for Rheumatoid Arthritis

Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients

Start date: December 2010
Phase: Phase 3
Study type: Interventional

The objective is to prove the equivalence in efficacy and safety of HD203 and Enbrel® in combination with Methotrexate in patients with rheumatoid arthritis.

NCT ID: NCT01270087 Completed - Clinical trials for Rheumatoid Arthritis

The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.

Start date: May 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether anti-inflammatory treatment with adalimumab (Humira) reduces endothelial activation in blood vessels in patients with active rheumatoid arthritis. Markers of endothelial activation are assessed in muscle tissue before treatment and after 3 months, and related to other biomarkers and clinical outcomes.

NCT ID: NCT01264211 Completed - Clinical trials for Rheumatoid Arthritis

Safety and Efficacy of the Combination of Diacerein 100 mg Daily and MTX Versus MTX Alone in the Treatment of Early Rheumatoid Arthritis (RA)

Start date: October 2010
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of Diacerein 100 mg daily versus placebo in reducing rheumatoid arthritis symptoms, when added to stable oral MTX therapy in patients with active early RA. To evaluate the safety of Diacerein 100 mg daily when administrated in combination with oral MTX therapy in those patients for up to 24 weeks To investigate a potential persistent effect, 4 weeks after Diacerein treatment is stopped (carry-over effect)

NCT ID: NCT01262118 Completed - Clinical trials for Rheumatoid Arthritis

Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

Start date: May 2011
Phase: Phase 1
Study type: Interventional

The purpose of study is to explore the effect of CP-690,550 (tasocitinib) on cholesterol metabolism in patients with active rheumatoid arthritis (RA).

NCT ID: NCT01256736 Completed - Clinical trials for Rheumatoid Arthritis

To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

Start date: March 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate 1 year extension study of the efficacy and the safety during treatment tocilizumab in patients completing treatment CWP-TCZ301 study with moderate to severe active RA and an inadequate response to current DMARD.

NCT ID: NCT01255761 Completed - Clinical trials for Rheumatoid Arthritis

A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects

PREDICT
Start date: November 2010
Phase: Phase 4
Study type: Interventional

Phase 4 study to evaluate a routine patient completed assessment (RAPID3) compared to a physician completed assessment (CDAI) to predict treatment success with subjects with moderate to severe rheumatoid arthritis

NCT ID: NCT01254331 Completed - Clinical trials for Rheumatoid Arthritis

An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment

Start date: February 2011
Phase: Phase 3
Study type: Interventional

This open-label, multi-center study in a local environment will evaluate the safety and the effect on disease activity with regard to reduction in signs and symptoms over 6 months of treatment in patients with moderate to severe active rheumatoid arthritis who experienced an inadequate response to a non-biologic DMARD. Tocilizumab 8 mg/kg will be administered as an intravenous infusion every 4 weeks for a total of 6 infusions as monotherapy or in combination with methotrexate (MTX). The anticipated time of study treatment is 24 weeks.

NCT ID: NCT01253291 Completed - Clinical trials for Rheumatoid Arthritis

A Study of Japanese Rheumatoid Arthritis Participants

Start date: May 2010
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety and tolerability of 48 weeks subcutaneous (SC) dosing with LY2127399 for participants who have participated in a prior LY2127399 clinical study. At the end of the 48-week treatment period, participants will participate in a 24-week follow-up period. Additional follow up after Week 72 may continue to assess B-cell recovery.

NCT ID: NCT01253265 Completed - Clinical trials for Rheumatoid Arthritis

A Study in Rheumatoid Arthritis

Start date: May 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of multiple doses of LY2439821 in Japanese patients with rheumatoid arthritis.

NCT ID: NCT01253226 Completed - Clinical trials for Rheumatoid Arthritis

A Study for Japanese Participants With Rheumatoid Arthritis (RA)

Start date: September 2009
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and tolerability of multiple doses of LY2127399 (tabalumab) in Japanese participants with RA. The study consists of a 20-week treatment period. All participants will be followed for up to 12 weeks after the last study drug administration.